Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review
Source : https://pubmed.ncbi.nlm.nih.gov/38646534/
Multiple Sclerosis (MS) management in individuals aged 55 and above presents unique challenges due to the complex interaction between aging, comorbidities, immunosenescence, and MS pathophysiology. This comprehensive review explores the...
Personalized management of MS in older adults requires comprehensive care, incorporating DMTs, non-pharmacologic approaches, and advance planning, emphasizing patient preferences and continuous monitoring to improve outcomes in this growing patient demographic.
Astrocyte signaling and interactions in Multiple Sclerosis
Source : https://pubmed.ncbi.nlm.nih.gov/38145604/
Multiple Sclerosis (MS) is a common cause of impairment in working-aged adults. MS is characterized by neuroinflammation and infiltration of peripheral immune cells to the brain, which cause myelin loss...
Astrocytes undergo significant changes in MS, impacting demyelination and repair. Understanding astrocytic signaling and interactions with nervous system cells can advance therapeutic strategies for MS management and recovery.
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
Source : https://pubmed.ncbi.nlm.nih.gov/37906325/
The recent success of anti-CD20 monoclonal antibody therapies in the treatment of multiple sclerosis (MS) has highlighted the role of B cells in the pathogenesis of MS. In people with...
Anti-CD20 therapies play a pivotal role in MS treatment, with diverse mechanisms and clinical implications. Shared decision-making incorporating efficacy, safety, and patient convenience can enhance outcomes and quality of life.
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
Source : https://pubmed.ncbi.nlm.nih.gov/38174776/
We are highly confident that, compared to placebo, two-year treatment with natalizumab, cladribine, or alemtuzumab decreases relapses more than with other DMTs. We are moderately confident that a two-year treatment...
Natalizumab, cladribine, and alemtuzumab significantly reduce relapses in RRMS over two years, but discontinuation due to adverse events is common. Further long-term studies comparing active agents are needed.
Multiple sclerosis: time for early treatment with high-efficacy drugs
Source : https://pubmed.ncbi.nlm.nih.gov/37851189/
This review addresses current changes in the approach to treating patients with multiple sclerosis (MS). The widely practiced approach of utilizing agents with lower treatment efficacy (LETA) at onset with...
Early initiation of high-efficacy treatment agents (HETA) in multiple sclerosis significantly reduces relapse rates and disability progression, shifting clinical practice towards proactive, patient-centric management for improved long-term outcomes.